Attention A T users. To access the menus on this page please perform the following steps.
1. Please switch auto forms mode to off.
2. Hit enter to expand a main menu option (Health, Benefits, etc).
3. To enter and activate the submenu links, hit the down arrow.
You will now be able to tab or arrow up or down through the submenu options to access/activate the submenu links.
Director, Minneapolis Primary Care and Specialty Care Integrated Care Community (ICC), Minneapolis VA Director, VA Midwest Health Care Network (VISN23) Specialty Care ICC Vice Chair and Professor, Department of Medicine, University of Minnesota
I am currently the Director of the Primary and Specialty Care Service Line at the Minneapolis VAHCS and the acting VA Midwest Health Care Network (VISN23) Specialty Care ICC Director. Over the past 12 years I have been actively involved in using large datasets and clinical trials to evaluate correlates of both acute and chronic kidney disease. I been involved in several studies that have evaluated causes and outcomes associated with acute kidney Injury. Additionally, I have used several VA datasets to similarly evaluate the long-term outcomes of acute kidney injury following cardiac surgery. Finally, I have also led a project evaluating the impact of physician payment on outcomes in patients on dialysis. Additionally, I have been active in several clinical trials. I have conducted 2 randomized controlled trials at the Minneapolis VA. The first involved 556 individuals randomized to nurse case management or usual care. As part of this study we were able to demonstrate a significant increase in blood pressure control rates in the case management group. The second study involved 601 individuals randomized to telehealth and interprofessional care vs. usual care. A secondary goal of this trial was management of blood pressure; However, this intervention was not able to demonstrate a difference in BP between groups. I was also the site PI for the SPRINT trial. For this trial we recruited 90 individuals with hypertension over an 8-month period. Currently, I am the Study Chair for VA Cooperative Study 597, The Diuretic Comparison Project (DCP). DCP is a point of care randomized controlled trial which aims to determine if Chlorthalidone is superior to HCTZ in preventing major cardiovascular events among patients with hypertension. We have randomized 13,500 individuals across 72 VA medical centers. Recently, we have been funded to evaluate the influence of beta blocker dialyzability on cardiovascular outcomes in hemodialysis patients. The planned sample size is 2,200 individuals.